Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2025 Financial Results SEATTLE, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the fourth quarter and full year ended December 31, 2025. “2025 was an outstanding year for Adaptive, marked by strong execution and meaningful progress across the business,” said Chad R...
Clearfield Reports First Quarter Fiscal 2026 Results Net sales from continuing operations grew 16% year over year to $34.3 million; Gross margin from continuing operations improved by 4 percentage points to 33.2%Clearfield Introduces NOVA™ Platform, Optimizing Scalability and Installation Simplicity for High-Density Fiber ConnectivityReiterates full year fiscal 2026 guidance of net sales from continuing operations in the range of $160 million to $170 million and EPS of $0.48 to $0.62Share buybacks totaled $5.2 million with $23.1 million remaining available for repurchases MINNEAPOLIS, Feb....
Adaptive Biotechnologies to Participate in Upcoming Investor Conferences SEATTLE, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the following investor conferences. BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference in Snowbird, UTParticipating on Tuesday, February 10, 2026TD Cowen 46th Annual Health Care Conferen...
Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2025 Financial Results on February 5, 2026 SEATTLE, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the fourth quarter and full year 2025 after market close on Thursday, February 5, 2026. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pac...
Clearfield Sets Fiscal First Quarter 2026 Earnings Call for Wednesday, February 4, 2026 MINNEAPOLIS, Jan. 21, 2026 (GLOBE NEWSWIRE) -- (NASDAQ: CLFD), the leader in community broadband fiber connectivity, today announced that it will release results for the first quarter of fiscal 2026, ended December 31, 2025, on Wednesday, February 4, 2026, after the close of the market. The company will host a conference call at 5:00 p.m. Eastern time (4:00 p.m. Central time) to discuss its financial results with the investment community. Financial results will be available on the Investor Relations ...
Adaptive Biotechnologies Announces Preliminary Fourth Quarter and Full Year 2025 Results Full year MRD revenue growth of 46% driven by clonoSEQ® testing volume SEATTLE, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced preliminary, unaudited results for the fourth quarter and full year ended December 31, 2025. Total revenue for the fourth quarter and full year 2025 was approx...
Adaptive Biotechnologies to Present at the 44th Annual J.P. Morgan Healthcare Conference SEATTLE, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the upcoming 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA. Adaptive Biotechnologies’ management is scheduled to present on Monday, January 12, 2026, at 4:30 p.m. Pacific Time / 7:30 ...
Two Directors at Clearfield Inc gave away/bought 11,960 shares at between 0.000USD and 30.060USD. The significance rating of the trade was 51/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors...
Adaptive Biotechnologies Announces Two Immune Receptor Licensing Agreements with Pfizer A target discovery agreement to identify disease-specific T-cell receptors (TCRs) in rheumatoid arthritis A data licensing agreement to access Adaptive’s proprietary TCR-antigen datasets for research and development in multiple immunology applications SEATTLE, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (NASDAQ: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disea...
AMREP Reports Second Quarter Fiscal 2026 Results HAVERTOWN, Pa., Dec. 12, 2025 (GLOBE NEWSWIRE) -- AMREP Corporation (NYSE:AXR) today reported net income of $1,200,000, or $0.22 per diluted share, for its 2026 fiscal second quarter ended October 31, 2025 compared to net income of $4,042,000, or $0.75 per diluted share, for the same period of the prior year. For the first six months of 2026, AMREP had net income of $5,892,000, or $1.09 per diluted share, compared to net income of $8,106,000, or $1.51 per diluted share, for the same period of 2025. Revenues were $9,398,000 and $27,250,000 f...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.